Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer

Biomedicine and Pharmacotherapy

Volumn 60, Issue 6, 2006, Pages 293-297

  Suen, D ^a   Chow, L W C ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Breast cancer; HER 2 oncogene

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; NOTTINGHAM PROGNOSTIC INDEX; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RELIABILITY; TUMOR VOLUME; UNIVARIATE ANALYSIS; BREAST TUMOR; CARCINOMA; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 33747149533     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.06.007     Document Type: Article

References (22)

1. Dorr F.A. Prognostic factors observed in current clinical trials. Cancer 71 Suppl. (1993) 2163-2168
2. Elston C.W., Ellis I.O., and Pinder S.E. Pathological prognostic factors in breast cancer. Crit. Rev. Oncol. Hematol. 31 (1999) 209-223
3. Haybittle J.L., Blamey R.W., Elston C.W., Johnson J., Doyle P.J., Campbell F.C., Nicholson R.I., and Griffiths K. A prognostic index in primary breast cancer. Br. J. Cancer 34 (1982) 361-366
4. Galea M.H., Blamey R.W., Elston C.E., et al. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res. Treat. 22 (1992) 207-219
5. Sjogren S., Inganas M., Lindgren A., Holmberg L., and Beigh J. Prognostic and predictive value of C-erbB2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 16 (1998) 462-469
6. AJCC. Manual for Staging for Cancer. 6th edn (2002), Lippincott, Philadelphia
7. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
8. Kollias J., Elston C.W., Ellis I.O., Robertson J.F., and Blamey R.W. Early-onset breast cancer - histopathological and prognostic considerations. Br. J. Cancer 75 (1997) 1318-1323
9. Kollias J., Murphy C.A., Elston C.W., Ellis I.O., Robertson J.F., and Blamey R.W. The prognosis of small primary breast cancers. Eur. J. Cancer 35 (1999) 908-912
10. st century and the Nottingham prognostic index. J. Clin. Pathol. 55 (2002) 86-87
11. Slamon D.J., Clark G.M., Wong S.G., Lewin W.J., Ullrich A., and Mc Guire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
12. Guerra I., Algorta J., Diaz de Otazu R., Pelayo A., and Farina J. Immunohistochemical prognostic index for breast cancer in young women. J Clin Pathol: Mol Pathol 56 (2003) 323-327
13. Hong Kong Cancer Registry (2002)
14. Borg A., Tandon A.K., Sigurdsson H., Clark G.M., Ferno M., Fugua S.A., Killander D., and Mac Guire W.L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50 (1990) 4322-4327
15. Winstanley J., Cooke T., Murray G.D., et al. The long term prognostic significance of c-erb-2 in primary breast cancer. Br. J. Cancer 63 (1991) 447-450
16. Paterson M.C., Dietrich K.D., Danyluk J., Paterson A.H., Lee A.W., Jamil N., Hanson J., Jenkins H., Krause B.E., and Mc Blain W.A. Correlation between c-erb-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 51 (1991) 566-567
17. Clark G.M., and McGuire W.L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 51 (1991) 944-948
18. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Annuals of Oncology 16 (2005) 1569-1583
19. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology (2006), Breast cancer - version 2
20. Hilsenbeck S.G., Ravdin P.M., de Moor C.A., Chamness G.C., Osborne C.K., and Clark G.M. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res. Treat. 52 (1998) 227-237
21. Van de Vijver M.J., He Y.D., Van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
22. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., and Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826